3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Sunitinib
27
Nivolumab
26
pembrolizumab
23
Sorafenib
17
Everolimus
14
Cyclophosphamide
13
Interleukin-2
10
Bevacizumab
10
Radiosurgery
9
spartalizumab
8
pazopanib
7
atezolizumab
7
Ipilimumab
7
Axitinib
7
fludarabine
6
aldesleukin
6
cabozantinib
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gemcitabine
5
peginterferon alfa-2b
4
avelumab
4
Nephrectomy
4
Irinotecan
4
Introns
4
Gene Expression Profiling
4
Capecitabine
4
lenvatinib
3
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Renal Cell
×
Tyrosine Kinase Inhibitors
×
Clear all
NCT01649180
2021-08-12
PrE0801
PrECOG, LLC.
Phase 2
Terminated
3 enrolled
7 charts